Literature DB >> 31699367

Long noncoding RNA FLVCR1-AS1 aggravates biological behaviors of glioma cells via targeting miR-4731-5p/E2F2 axis.

Zhiyuan Yan1, Weizhong Zhang1, Ye Xiong1, Yunhui Wang1, Zequn Li2.   

Abstract

Long noncoding RNAs (lncRNAs) display essential roles in cancer progression. FLVCR1-AS1 is a rarely investigated lncRNAs involved in various human cancers, such as hepatocellular carcinoma and lung cancer. However, its function in glioma has not been clarified. In our study, we found that FLVCR1-AS1 was highly expressed in glioma tissues and cell lines. And upregulation of FLVCR1-AS1 predicted poor prognosis in patients with glioma. Moreover, FLVCR1-AS1 knockdown inhibited proliferation, migration and invasion of glioma cells. Through bioinformatics analysis, we identified that FLVCR1-AS1 was a sponge for miR-4731-5p to upregulate E2F2 expression. Moreover, rescue assays indicated that FLVCR1-AS1 modulated E2F2 expression to participate in glioma progression. Altogether, our research demonstrates that the FLVCR1-AS1/miR-4731-5p/E2F2 axis is a novel signaling in glioma and may be a potential target for tumor therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  E2F2; FLVCR1-AS1; Glioma; Long noncoding RNA; miR-4731-5p

Year:  2019        PMID: 31699367     DOI: 10.1016/j.bbrc.2019.10.106

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Long non‑coding RNA FLVCR1‑AS1 promotes glioma cell proliferation and invasion by negatively regulating miR‑30b‑3p.

Authors:  Weida Gao; Hongbin Li; Yang Liu; Yao Zhang; Hong Zhao; Fei Liu
Journal:  Mol Med Rep       Date:  2020-05-15       Impact factor: 2.952

2.  LncRNA DDX11-AS1 Exerts Oncogenic Roles in Glioma Through Regulating miR-499b-5p/RWDD4 Axis.

Authors:  Yanyan Zheng; Jing Xie; Xiaomin Xu; Xiaoguo Yang; Yi Zhou; Qiong Yao; Ye Xiong
Journal:  Onco Targets Ther       Date:  2021-01-08       Impact factor: 4.147

3.  lncRNA FLVCR1‑AS1 drives colorectal cancer progression via modulation of the miR‑381/RAP2A axis.

Authors:  Yi Han; Xiaoyan Wang; Enqiang Mao; Boyong Shen; Liang Huang
Journal:  Mol Med Rep       Date:  2020-12-14       Impact factor: 2.952

4.  CRNDE/ETS1/GPR17 Facilitates the Proliferation, Migration, and Invasion of Glioma.

Authors:  Yan Hu; Haitao Luo; Xingen Zhu; Hua Guo
Journal:  Comput Math Methods Med       Date:  2021-10-26       Impact factor: 2.238

5.  Identification of Prognostic Factors Related to Super Enhancer-Regulated ceRNA Network in Metastatic Lung Adenocarcinoma.

Authors:  Mingjiang Li; Bo Yang; Xiaoping Li; Haixia Ren; Liang Zhang; Lei Li; Wei Li; Xuhui Wang; Honggang Zhou; Weidong Zhang
Journal:  Int J Gen Med       Date:  2021-10-01

6.  Tumor suppressive role of microRNA-4731-5p in breast cancer through reduction of PAICS-induced FAK phosphorylation.

Authors:  Lei Lang; Jing Tao; Chaomei Yang; Wei Li
Journal:  Cell Death Discov       Date:  2022-04-04

7.  miR-4731-5p Enhances Apoptosis and Alleviates Epithelial-Mesenchymal Transition through Targeting RPLP0 in Non-Small-Cell Lung Cancer.

Authors:  Chang Chang; Meilin Xu
Journal:  J Oncol       Date:  2022-03-17       Impact factor: 4.375

8.  Role of long intergenic non-protein coding RNA 01857 in hepatocellular carcinoma malignancy via the regulation of the microRNA-197-3p/anterior GRadient 2 axis.

Authors:  Jiangang Bi; Yusheng Guo; Qi Li; Liping Liu; Shiyun Bao; Ping Xu
Journal:  PLoS One       Date:  2021-11-18       Impact factor: 3.240

9.  LncRNA FLVCR1-AS1 mediates miR-23a-5p/SLC7A11 axis to promote malignant behavior of cervical cancer cells.

Authors:  Xi Zhou; Xia Zhao; ZhouYi Wu; Yan Ma; Heng Li
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

10.  LncRNA FLVCR1-AS1 promotes proliferation, migration and activates Wnt/β-catenin pathway through miR-381-3p/CTNNB1 axis in breast cancer.

Authors:  Zhiyu Pan; Junbin Ding; Zhen Yang; Huaqing Li; Hongjian Ding; Qian Chen
Journal:  Cancer Cell Int       Date:  2020-06-05       Impact factor: 5.722

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.